Immortalization of Epithelial Cells and Methods of Use

Patent metadata

Field	Value
Publication number	US-2016289644-A1
Application number	US-201615040783-A
Country	US
Kind code	A1
Filing date	Feb 10, 2016
Priority date	Nov 12, 2010
Publication date	Oct 6, 2016
Grant date	—

Abstract

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.

First claim

1 - 58 . (canceled)

59 . A method for continuously culturing non-keratinocyte epithelial cells, comprising:
(a) culturing non-keratinocyte epithelial (NKE) cells isolated from tissue of a mammal, or cells derived therefrom, in the presence of feeder cells or a medium conditioned with feeder cells; and a calcium-containing medium; and (b) inhibiting the activity of Rho kinase (ROCK) in the feeder cells, the NKE cells or both during the culturing, thereby generating a cell culture comprising a population of NKE cells, wherein: the cell culture does not include embryonic stem cells, the population of the NKE cells in the cell culture is capable of 60 or more population doublings, and the NKE cells isolated from tissue of a mammal, or cells derived therefrom, not exposed to (a) and (b) are not capable of 60 population doublings.

60 . The method of claim 59 , wherein the NKE cells are derived from primary cells.

61 . The method of claim 60 , wherein the primary cells are from epithelial tissue of a human patient.

62 . The method of claim 59 , wherein the NKE cells are not derived from primary cells.

63 . The method of claim 59 , wherein the NKE cells are derived from a population of tumor NKE cells.

64 . The method of claim 59 , wherein the NKE cells are derived from non-immortalized NKE cells obtained from epithelial tissue.

65 . The method of claim 59 , wherein the NKE cells are derived from differentiated NKE cells obtained from epithelial tissue.

66 . The method of claim 59 , wherein the NKE cells are derived from organ-specific NKE cells obtained from epithelial tissue.

67 . The method of claim 59 , wherein the NKE cells are derived from cells selected from the group consisting of squamous cells, columnar cells, adenomatous cells and transitional epithelial cells.

68 . The method of claim 67 , wherein the NKE cells are derived from cells selected from the group consisting of prostate cells, mammary cells, hepatocytes, pancreatic islet cells, pulmonary epithelial cells, kidney cells, bladder cells, stomach epithelial cells, large intestinal epithelial cells, small intestinal epithelial cells, urethral epithelial cells, testicular epithelial cells, ovarian epithelial cells, thyroid cells, parathyroid cells, adrenal cells, thymus cells, gall bladder cells and pituitary cells.

69 . The method of claim 59 , wherein the calcium-containing medium comprises serum or a serum replacement.

70 . The method of claim 59 , wherein the feeder cells are proliferating or non-proliferating fibroblasts.

71 . The method of claim 59 , wherein inhibiting the activity of ROCK comprises culturing the NKE cells in the presence of one or more of a small molecule inhibitor of Rho kinase 1 (ROCK 1), a small molecule inhibitor of Rho kinase 2 (ROCK 2), a RNAi molecule directed to ROCK 1, and a RNAi molecule directed to ROCK 2.

72 . The method of claim 71 , wherein the small molecule ROCK inhibitor is selected from the group consisting of Y-27632, HA1100 hydrochloride, HA1077 and GSK429286.

73 . The method of claim 59 , wherein the population of the NKE cells in the cell culture express basal epithelial cell marker P63.

74 . The method of claim 73 , wherein the basal epithelial cell marker P63 is expressed in the population of NKE cells after about 30 passages.

75 . The method of claim 73 , wherein the basal epithelial cell marker P63 is expressed in the population of NKE cells after about 80 passages.

76 . The method of claim 59 , wherein the population of the NKE cells in the cell culture is capable of 80 or more population doublings.

77 . The method of claim 59 , wherein the population of the NKE cells in the cell culture is capable of 100 or more population doublings.

78 . The method of claim 59 , wherein the population of the NKE cells in the cell culture is capable of 120 or more population doublings.

Assignees

• Univ Georgetown

Inventors

• Schlegel Richard
• Liu Xuefeng

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C12N5/0625

  Epidermal cells, skin cells; Cells of the oral mucosa · CPC title